09:29 AM EST - Numinus Wellness Inc. : Announced plans to significantly expand its psychedelics research laboratory by late 2021. Numinus Wellness Inc. A 7,500 square-foot expansion will be developed and housed in an existing Numinus-leased building adjacent to the current lab. The expansion announcement comes days after Numinus received amendments to its federal licence under Canada's Controlled Drugs and Substances Act to allow the possession, production, assembly, sale, export and/or delivery of a variety of psychedelics including Ketamine, LSD, Mescaline, N,N-Dimethyltryptamine (DMT), N-Methyl-3,4, methylenedioxyamphetamine (MDMA), Psilocin and Psilocybin. Numinus Wellness Inc.
shares V.NUMI are trading unchanged at $1.33.
